Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 19Terminated 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Neoplasms by Site 1Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bronchial Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × napabucasin × Clear all
NCT02826161 2023-11-15

CanStem43L

Sumitomo Pharma America, Inc.

Phase 3 Terminated
4 enrolled 6 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT02851004 2021-09-05

Special Combination of BBI608 and Pembrolizumab

National Cancer Center Hospital East

Phase 1/2 Terminated
55 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡